Contentious Tax Bulletin
Tax Investigations Partner, Andrew Park, provides a round up of the most recent and significant contentious tax news. Read more here...
Our accounting and tax experts understand the unique concerns of the biotechnology industry and will support you with guidance based on in-depth sector knowledge.
With offices in London and Cambridge, and many years’ worth of experience working with biotech companies and start-ups, we are perfectly positioned to provide biotechs with specialist support and advice.
We offer an extensive range of services, which ensures you have access to highly relevant knowledge and resources, wherever your objectives and challenges lie.
No matter the services you choose, we ensure you understand the opportunities available to you and help you comply with relevant legislation while supporting the long-term success of your company.
Despite facing adversity during the pandemic, the recent surge in funding for private biotech companies has strengthened their reputation as innovative and buoyant companies.
With the biotech sector likely to remain strong in the future, and an increasing investor focus, now is an important time as any to seek expert support regarding the strategic planning of your company, financial support, and tax advice.
We will work with you to provide the right solutions to your company, so you can focus on running it.
Contact us today to find out more about how we can help you
Tax Investigations Partner, Andrew Park, provides a round up of the most recent and significant contentious tax news. Read more here...
The timeline for the issue of the next Charities SORP is now known following a recent annual sector update from the Charity Commission. Read more in our blog here...
Monthly healthcare updates with Holly Gibson, Price Bailey's healthcare expert offering advice and insight on topical issues affecting the healthcare industry today.
Our first article in our supply chain series delves into the supply chain challenges faced by UK businesses in September 2024. Find out more...